Antiemetic Control with Palonosetron in Patients with Gastrointestinal Cancer Receiving a Fluoropyrimidine-Based Regimen in Addition to Either Irinotecan or Oxaliplatin: A Retrospective Study

Authors:
  • GPGary Phillips
    Gary Phillips
  • JRJoshua Reardon
    Joshua Reardon
  • DEDavid Efries
    David Efries
  • YSYahna Smith
    Yahna Smith
  • LWLynn Weatherby
    Lynn Weatherby
  • KJKim Juergens
    Kim Juergens
  • JRJeffrey Rose
    Jeffrey Rose
  • NGNiesha Griffith
    Niesha Griffith
  • TBTanios Bekaii-Saab
    Tanios Bekaii-Saab

Abstract
Background: For moderately emetogenic chemotherapy, palonosetron (PALO) is reported to provide complete control of chemotherapy-induced nausea and vomiting (CINV) in 69% of patients. Prior to August 2009, our gastrointestinal (GI) cancer patients receiving the moderately emetogenic compounds oxaliplatin or irinotecan plus a fluoropyrimidine regimen received ondansetron and dexamethasone orally on day 1 of chemotherapy for CINV prevention. Beginning in August of 2009, ondansetron was replaced by PALO 0.25 mg (intravenous push). Methods: This is a single-institution retrospective study of GI cancer patients who received oxaliplatin or irinotecan plus a fluoropyrimidine. Failure of an antiemetic regimen was defined as grade ≥1 vomiting or grade ≥2 nausea (Common Terminology Criteria for Adverse Events, version 3) on days 1 through 5 following chemotherapy. Patients were divided for analysis into pre-PALO and post-PALO cohorts. Fisher’s exact test compared cohort differences. Results: A total of 305 patients were included in the study, with 157 patients in the pre-PALO cohort and 148 in the post-PALO cohort. For all patients, the risk of antiemetic failure was reduced from 50.3% [95% confidence interval (CI) 42.2–58.4%] to 28.4% (95% CI 21.3–36.4%) with PALO. This reduction in the relative risk of antiemetic failure was observed in all subgroups. Conclusion: The addition of PALO may provide increased control of CINV for the moderately emetogenic regimens of oxaliplatin or irinotecan plus a fluoropyrimidine in GI cancer patients.

This publication has 17 references indexed in Scilit: